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Plasma loads of torque teno virus (TTV) among individuals differ extensively beginning early in life,
suggesting a role for innate immunity. Here, congenital mannose-binding lectin deficiencies, but not deficien-
cies in respiratory ciliary function, correlated with increased TTV loads. Notably, however, the presence of
either disorder was associated with particularly high TTV loads.
Torque teno virus (TTV) is a small, nonenveloped single-
stranded DNA virus. Human TTV is classified in 29 genetically
distinct species, which cluster in 5 branches (genogroups 1 to 5;
http://www.ictvonline.org/virusTaxonomy.asp?version2009) in
phylogenetic trees. TTV causes chronic, possibly lifelong
viremias in most people regardless of age, health status, and
other variants. In fact, 70% to 90% of the general population
worldwide is viremic, and the virus has not yet been associated
with any disease with certainty, suggesting a remarkable adap-
tation to its host (2, 11).
Individual viremia loads (VLs) of TTV differ extensively for
reasons that remain to be defined (17). Recently, the number
of coinfecting viral variants was identified as a factor (16).
However, VLs differed extensively also if this number was
constant, suggesting the existence of a further determinant(s)
of VL size. Because there are already wide differences between
VLs in individuals early in life (18, 22), we reasoned that innate
immunity might be involved. Therefore, we considered it in-
teresting to investigate whether a mannose-binding lectin
(MBL) deficit, probably the most common congenital deficit of
innate immunity, may have an impact. MBL, encoded by gene
MBL2 on chromosome 10, is a pattern recognition protein that
exerts its protective action by activating the complement cas-
cade through an antibody-independent pathway triggered by
its binding to pathogen surfaces and other mechanisms (13).
MBL is probably most important in antibacterial defenses (14)
but also plays a significant role against viruses; indeed, MBL2
polymorphisms known to lead to lower-than-normal blood
concentrations of functional MBL have been linked with an
increased susceptibility to several enveloped and nonenve-
loped viruses (3, 4, 6, 8, 10, 12, 24, 25, 26). Furthermore,
because the airways are colonized by TTV early in life and may
represent a port of body entry (18), we conducted the investi-
gation with patients being evaluated to confirm or exclude the
presence of primary ciliary dyskinesia (PCD). This much less
common (1 case per 10,000 people) congenital disorder of
innate immunity consists of a defective motion of the cilia
lining the lower and upper respiratory tract that leads to sig-
nificantly increased susceptibility to respiratory infections (15).
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TABLE 1. TTV detection and VLs in the study patients, subdivided
by expected MBL level and type of ciliary dyskinesia
MBL levela Ciliarydefect
TTV in whole blood
No. of
patients
positive/no.
examined (%)
Median VL (95% CL)b
Any PCD 36/52 (69) 397 (140–2,068)
SCD 33/46 (72) 2,305 (1,096–8,340)
Normal PCD 11/19 (58) 182 (100–1,175)
SCD 10/14 (71) 2,410 (100–10,580)
Moderately low PCD 19/26 (73) 710 (125–6,540)
SCD 16/22 (70) 5,000 (430–14,160)
Very low/undetectable PCD 6/7 (86) 14,830 (240–2,347,000)c
SCD 7/10 (70) 1,964 (100–21,094)
a Following the current nomenclature, homozygosity for the wild-type first
exon is denoted genotype A/A, homozygosity for low-MBL first exon is denoted
O/O, and heterozygosity is denoted A/O. Similarly, homozygosity for the wild-
type promoter is denoted Y/Y, homozygosity for the low-MBL promoter is
denoted X/X, and heterozygosity is denoted Y/X. The normal-MBL-level cate-
gory corresponded to genotypes A/A plus Y/Y and A/A plus Y/X. The moder-
ately-low-MBL-level category corresponded to genotypes A/O plus Y/Y and A/A
plus X/X. The very-low-to-undetectable-MBL-level category corresponded to
genotypes O/O plus Y/Y and A/O plus X/Y.
b DNA copies per ml. The patients who tested negative were arbitrarily as-
signed a value of 100. CL, confidence limits.
c Significantly different from the normal-MBL-level PCD group at a P value of
0.02 (Mann-Whitney test). No other significant differences were detected.
692
Its diagnosis is often missed early in life, but the dysfunction is
evident from the time of embryonic development (27).
After we received their informed consent, patients were
consecutively enrolled at the Department of Pediatrics of the
Pisa University Hospital from January 2008 to July 2010. Based
on phenotypic criteria (genetic diagnosis is not recommended,
due to the multiple existing and newly emerging phenotypes
[1]), including results of ciliary motion analysis and ultrastruc-
tural assessment of the cilia, ciliary function after ciliogenesis
in culture of nasal brushing samples, and other data, 52 pa-
tients (30 males and 22 females; median age, 11 years [95%
confidence limits, 8 to 20 years]; 33 with situs inversus, an
abnormality often accompanying PCD) were recognized to be
affected by PCD, while in 46 (21 males and 25 females; median
age, 14 years [95% confidence limits, 11 to 22 years]), the
defect was attributed to viral or bacterial respiratory infections
or pollution-induced irritant injury of the mucosa (secondary
ciliary dyskinesia [SCD]). DNA extracted from 200 l of whole
blood by the BioRobot EZ1 (Qiagen GmbH, Hilden, Ger-
many) was used for both MBL2 genotyping and TTV analysis.
The four MBL2 single-nucleotide polymorphisms—3 in the
first exon (codons 52, 54, and 57) and 1 in the promoter—that,
alone or in combination, determine MBL deficiencies were
investigated by specific PCR amplification and sequencing.
The frequencies of MBL2 variants in the patients (data not
shown) were consistent with results of previous surveys in the
European population (21). Finally, based on MBL2 make-up,
the patients were subdivided into three groups depending on
expected blood level of MBL (normal, moderately low, and
very low to undetectable) according to established criteria (Ta-
ble 1) (9). TTV viremia was determined by a quantitative
single-step TaqMan PCR targeting a highly conserved segment
of the untranslated region. The analytical sensitivity was 100
copies/ml of blood, as determined using TTV-negative serum
spiked with different numbers of a standard DNA template
and extracted and amplified with a protocol studied to achieve
this sensitivity (7).
Sixty-nine of the 98 total patients (70%) had TTV-positive
reactions, with VLs between 125 and 11,000,000 DNA copies
per ml of whole blood (Table 1). These values were somewhat
lower than those in previous reports by our group (23), likely
due to the different DNA extraction method used (19, 20).
However, since all samples were processed in the same man-
ner, they permitted comparison of the various subgroups of
patients. Figure 1 shows that, although there was a low degree
of significance, the TTV VLs were inversely correlated to the
expected blood levels of MBL, indicating that this effector of
innate immunity is likely to exert a protective role against
TTV. In contrast, PCD patients showed no significant differ-
ences in infection rates relative to SCD and, although the
difference was not statistically different, had slightly greater
VLs (Table 1), indicating that a congenital defect of respira-
tory ciliary motion, per se, does not lead to especially elevated
VLs, at least relative to SCD. However, when the patients were
sorted by MBL level and type of ciliary dyskinesia, the small
group (7 patients) with both PCD and very low or undetectable
MBL stood out for particularly high VLs (Table 1).
In conclusion, consistent with findings from other viral in-
fections (4, 6, 8, 10, 12, 24–26), MBL2 polymorphisms known
to lead to MBL deficiencies were associated with higher TTV
VLs than was wild-type MBL2, supporting the view that innate
immunity efficiency contributes to determining the TTV VL
size. The increase was modest but might have been greater had
we examined subjects earlier in infancy, when the role of MBL
in antimicrobial resistance is most important (5, 28). Since
MBL exerts its protective activity through a variety of biolog-
ical effects, including complement activation, phagocytosis
stimulation, and cytokine synthesis modulation (28), future
experiments will have to investigate their relative importance
in this effect. Also, that the few patients congenitally deficient
in both MBL levels and respiratory ciliary function had partic-
ularly elevated VLs suggests that the coexistence of different
flaws in innate immunity may have a cooperative facilitating
effect on TTV. Thus, it would be important to clarify whether
and how extensively other defects of innate immunity, but also
adaptive immunity, impact TTV viremia size and stability over
time.
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